The incidence of cutaneous T-cell lymphoma increased in US patients aged 0-29 years from 1997 to 2019, with larger rises in younger children, males, and Hispanics.

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...

Citius Oncology Inc. has commercially launched Lymphir, a treatment for Stage I–III cutaneous T-cell lymphoma, the Cranford-based firm announced Dec. 1. In August 2024, the U.S. Food and Drug ...

HOUSTON -- Patients with advanced or refractory cutaneous T-cell lymphoma (CTCL) achieved near-100% disease control with single-agent immunotherapy or an immuno-oncology (IO) combination, a small ...

US biotech Citius Oncology, the oncology-focused subsidiary of Citius Pharmaceuticals, has entered into an exclusive distribution agreement with Unipha, a leading international healthcare services ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with ...

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma. The Food and Drug Administration has approved Lymphir (denileukin ...

Among patients with mycosis fungoides (MF) and Sézary syndrome (SS), the T-cell receptor (TCR) clonal Vb20 segment was significantly associated with advanced-stage disease, folliculotropism with ...